Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Tisagenlecleucel in pediatric R/R B-cell ALL

Andre Baruchel • 28 Jun 2020
EHA 2020
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab CAR-T Inotuzumab ozogamicin Tisagenlecleucel
B2001X

Andre Baruchel, MD, PhD, of Hôpital Robert Debre, Paris, France, discusses tisagenlecleucel for pediatric/young adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) as evaluated in the B2001X study (NCT03123939) focusing on prior exposure to blinatumomab and inotuzumab. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andre Baruchel

2:45
The need for alternative development pathways for CAR T-cell products
Andre Baruchel • 16 Feb 2024
4:16
The challenges with CAR T-cell therapy for T-ALL and the progress made to overcome these challenges
Andre Baruchel • 16 Feb 2024
4:06
CAR-T therapy in ALL: exploring dual-targeting of CD19 & CD22 to overcome resistance
Andre Baruchel • 16 Feb 2024
7:17
B-cell ALL with IGH-IL3 rearrangement and eosinophilia
Andre Baruchel • 16 Jul 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals